Abstract
The gastrointestinal tract is one of the most common sites for the development of primary neoplasms arising in patients with pre-existing infection with the human immunodeficiency virus (HIV). Over the past decade, new information on the clinical manifestation, natural history, treatment options, and related toxicity have been reported, mostly notably the integration of highly active antiretroviral therapy (HAART). The following is a concise review summarizing the current state-of-the-art for GI tract malignancies in the HIV-positive patient and is designed to assist the clinical oncology team in developing a rationale plan when caring for these patients.
Similar content being viewed by others
References
Gervaz P, Allal AS, Villiger P, et al. Squamous cell carcinoma of the anus: another sexually transmitted disease. Swiss Med Wkly 2003;133:353–359.
American Cancer Society. Cancer Facts & Figures 2004. 2004:4.
Frisch M. On the etiology of anal squamous carcinoma. Dan Med Bull 2002;49:194–209.
Palefsky JM. Anal human papillomavirus infection and anal cancer in HIV-positive individuals: an emerging problem. Aids 1994;8:283–295.
Rabkin CS, Yellin F. Cancer incidence in a population with a high prevalence of infection with human immunodeficiency virus type 1. J Natl Cancer Inst 1994;86:1711–1716.
Daling JR, Madeleine MM, Johnson LG, et al. Human papillomavirus, smoking, and sexual practices in the etiology of anal cancer. Cancer 2004;101:270–280.
Tseng HF, Morgenstern H, Mack TM, et al. Risk factors for anal cancer: results of a population-based case-control study. Cancer Causes Control 2003;14:837–846.
Daling JR, Weiss NS, Hislop TG, et al. Sexual practices, sexually transmitted diseases, and the incidence of anal cancer. N Engl J Med 1987;317:973–977.
Holly EA, Whittemore AS, Aston DA, et al. Anal cancer incidence: genital warts, anal fissure or fistula, hemorrhoids, and smoking. J Natl Cancer Inst 1989;81:1726–1731.
Penn I. Cancers of the anogenital region in renal transplant recipients. Analysis of 65 cases. Cancer 1986;58:611–616.
Piketty C, Darragh TM, Da Costa M, et al. High prevalence of anal human papillomavirus infection and anal cancer precursors among HIV-infected persons in the absence of anal intercourse. Ann Intern Med 2003;138:453–459.
Durante AJ, Williams AB, Da Costa M, et al. Incidence of anal cytological abnormalities in a cohort of human immunodeficiency virus-infected women. Cancer Epidemiol Biomarkers Prev 2003;12:638–642.
Palefsky JM, Holly EA, Ralston ML, et al. Anal squamous intraepithelial lesions in HIV-positive and HIV-negative homosexual and bisexual men: prevalence and risk factors. J Acquir Immune Defic Syndr Hum Retrovirol 1998;17:320–326.
Drobacheff C, Dupont P, Mougin C, et al. Anal human papillomavirus DNA screening by Hybrid Capture II in human immunodeficiency virus-positive patients with or without anal intercourse. Eur J Dermatol 2003;13:367–371.
Minkoff H, Ahdieh L, Massad LS, et al. The effect of highly active antiretroviral therapy on cervical cytologic changes associated with oncogenic HPV among HIV-infected women. Aids 2001;15:2157–2164.
Heard I, Schmitz V, Costagliola D, et al. Early regression of cervical lesions in HIV-seropositive women receiving highly active antiretroviral therapy. Aids 1998;12:1459–1464.
Lillo FB, Ferrari D, Veglia F, et al. Human papillomavirus infection and associated cervical disease in human immunodeficiency virus-infected women: effect of highly active antiretroviral therapy. J Infect Dis 2001;184:547–551.
Schuman P, Ohmit SE, Klein RS, et al. Longitudinal study of cervical squamous intraepithelial lesions in human immunodeficiency virus (HIV)-seropositive and at-risk HIV-seronegative women. J Infect Dis 2003;188:128–136.
Nigro ND, Seydel HG, Considine B, et al. Combined preoperative radiation and chemotherapy for squamous cell carcinoma of the anal canal. Cancer 1983;51:1826–1829.
Beahrs O. Janeway Lecture. Management of cancer of the anus. AJR Am J Roentgenol 1979;133:790–795.
Boman BM, Moertel CG, O’Connell MJ, et al. Carcinoma of the anal canal. A clinical and pathologic study of 188 cases. Cancer 1984;54:114–125.
Leichman L, Nigro N, Vaitkevicius VK, et al. Cancer of the anal canal. Model for preoperative adjuvant combined modality therapy. Am J Med 1985;78:211–215.
Cummings B, Keane T, Thomas G, et al. Results and toxicity of the treatment of anal canal carcinoma by radiation therapy or radiation therapy and chemotherapy. Cancer 1984;54:2062–2068.
Meeker WR, Jr., Sickle-Santanello BJ, Philpott G, et al. Combined chemotherapy, radiation, and surgery for epithelial cancer of the anal canal. Cancer 1986;57:525–529.
Flam MS, John M, Lovalvo LJ, et al. Definitive nonsurgical therapy of epithelial malignancies of the anal canal. A report of 12 cases. Cancer 1983;51:1378–1387.
Michaelson RA, Magill GB, Quan SH, et al. Preoperative chemotherapy and radiation therapy in the management of anal epidermoid carcinoma. Cancer 1983;51:390–395.
Sischy B, Doggett RL, Krall JM, et al. Definitive irradiation and chemotherapy for radiosensitization in management of anal carcinoma: interim report on Radiation Therapy Oncology Group study no. 8314. J Natl Cancer Inst 1989;81:850–856.
Tveit KM, Karlsen KO, Fossa SD, et al. Primary treatment of carcinoma of the anus by combined radiotherapy and chemotherapy. Scand J Gastroenterol 1989;24:1243–1247.
Cummings BJ, Keane TJ, O’Sullivan B, et al. Epidermoid anal cancer: treatment by radiation alone or by radiation and 5-fluorouracil with and without mitomycin C. Int J Radiat Oncol Biol Phys 1991;21:1115–1125.
Eschwege F, Lasser P, Chavy A, et al. Squamous cell carcinoma of the anal canal: treatment by external beam irradiation. Radiother Oncol 1985;3:145–150.
Dobrowsky W. Radiotherapy of epidermoid anal canal cancer. Br J Radiol 1989;62:53–58.
Doggett SW, Green JP, Cantril ST. Efficacy of radiation therapy alone for limited squamous cell carcinoma of the anal canal. Int J Radiat Oncol Biol Phys 1988;15:1069–1072.
Martenson JA Jr, Gunderson LL. External radiation therapy without chemotherapy in the management of anal cancer. Cancer 1993;71:1736–1740.
Flam M, John M, Pajak TF, et al. Role of mitomycin in combination with fluorouracil and radiotherapy, and of salvage chemoradiation in the definitive nonsurgical treatment of epidermoid carcinoma of the anal canal: results of a phase III randomized intergroup study. J Clin Oncol 1996;14:2527–2539.
Epidermoid anal cancer: results from the UKCCCR randomised trial of radiotherapy alone versus radiotherapy, 5-fluorouracil, and mitomycin. UKCCCR Anal Cancer Trial Working Party. UK Co-ordinating Committee on Cancer Research. Lancet 1996;348:1049–1054.
Martenson JA, Lipsitz SR, Wagner H Jr, et al. Initial results of a phase II trial of high dose radiation therapy, 5-fluorouracil, and cisplatin for patients with anal cancer (E4229): an Eastern Cooperative Oncology Group study. Int J Radiat Oncol Biol Phys 1996;35:745–749.
Cho DS, Shieh G, Kuber N, et al. Definitive radiotherapy in the combined modality treatment of HIV anal carcinoma. Proceedings of the 20th American Society of Clinical Oncology, 2001 [Abstr 2350].
Hoecht S. Cancer of the anal canal and HIV-infection: toxicity and results of radiochemotherapy or radiotherapy. Proceedings of the 19th American Society of Clinical Oncology, 2000 [Abstr 1848].
Allen-Mersh T, Goldstone S, Sparano A, Elrafei T, Bower M. Is chemoradiation the treatment of choice for anal squamous cell carcinoma developing in HIV-positive patients with access to highly active antiretroviral therapy? Procceding of the 2004 Gastrointestinal Cancers Symposium: Current Status and Future Directions for SPrevention and Management, [Abstr 233]; p. 156.
Cote TR, Biggar RJ, Rosenberg PS, et al. Non-Hodgkin’s lymphoma among people with AIDS: incidence, presentation and public health burden. AIDS/Cancer Study Group. Int J Cancer 1997;73:645–650.
Biggar RJ, Rosenberg PS, Cote T. Kaposi’s sarcoma and non-Hodgkin’s lymphoma following the diagnosis of AIDS. Multistate AIDS/Cancer Match Study Group. Int J Cancer 1996;68:754–758.
Levine AM, Seneviratne L, Tulpule A. Incidence and management of AIDS-related lymphoma. Oncology (Huntingt) 2001;15:629–639.
Eltom MA, Jemal A, Mbulaiteye SM, et al. Trends in Kaposi’s sarcoma and non-Hodgkin’s lymphoma incidence in the United States from 1973 through 1998. J Natl Cancer Inst 2002;94:1204–1210.
Levine AM. Acquired immunodeficiency syndrome-related lymphoma. Blood 1992;80:8–20.
Levine AM, Gill PS, Meyer PR, et al. Retrovirus and malignant lymphoma in homosexual men. JAMA 1985;254:1921–1925.
Danzig JB, Brandt LJ, Reinus JF, Klein RS. Gastrointestinal malignancy in patients with AIDS. Am J Gastroenterol 1991;86:715–718.
Ullrich R, Zeitz M, Riecken EO. Enteric immunologic abnormalities in human immunodeficiency virus infection. Semin Liver Dis 1992;12:167–174.
Pluda JM, Venzon DJ, Tosato G, et al. Parameters affecting the development of non-Hodgkin’s lymphoma in patients with severe human immunodeficiency virus infection receiving antiretroviral therapy. J Clin Oncol 1993;11:1099–1107.
Shibata D, Weiss LM, Hernandez AM, et al. Epstein-Barr virus-associated non-Hodgkin’s lymphoma in patients infected with the human immunodeficiency virus. Blood 1993;81:2102–2109.
Levine AM, Said JW. Management of acquired immunodeficiency syndrome-related lymphoma, in Non-Hodgkins Lymphoma. Mauch P, ed. Lippincott, Williams and Wilkins, Philadelphia, PA, 2004; pp. 613–627.
Hernandez JA, Navarro JT, Ribera JM, et al. Primary gastrointestinal lymphoma in patients infected with HIV: study of 15 cases in a series of 76 patients with non-Hodgkin’s lymphoma and HIV infection. Med Clin (Barc) 1999;112:222–224.
Heise W, Arasteh K, Mostertz P, et al. Malignant gastrointestinal lymphomas in patients with AIDS. Digestion 1997;58:218–224.
Crump M, Gospodarowicz M, Shepherd FA. Lymphoma of the gastrointestinal tract. Semin Oncol 1999;26:324–337.
AliMohamed F, Lule GN, Nyong’o A, et al. Prevalence of Helicobacter pylori and endoscopic findings in HIV seropositive patients with upper gastrointestinal tract symptoms at Kenyatta National Hospital, Nairobi. East Afr Med J 2002;79:226–231.
Eidt S, Schrappe M, Fischer R. Analysis of antral biopsy specimens for evidence of acquired mucosa-associated lymphoid tissue in HIV1-seropositive and HIV1-negative patients. Scand J Gastroenterol 1995;30:635–639.
Wotherspoon AC, Diss TC, Pan L, et al. Low grade gastric B-cell lymphoma of mucosa associated lymphoid tissue in immunocompromised patients. Histopathology 1996;28:129–134.
Tokunaga O, Watanabe T, Shimamoto Y, Tokudome S. Primary T-cell lymphoma of the gastrointestinal tract associated with human T-cell lymphotropic virus type I. An analysis using in situ hybridization and polymerase chain reaction. Cancer 1993;71:708–716.
Ioachim HL, Antonescu C, Giancotti F, Dorsett B, Weinstein MA. EBV-associated anorectal lymphomas in patients with acquired immune deficiency syndrome. Am J Surg Pathol 1997;21:997–1006.
Imrie KR, Sawka CA, Kutas G, et al. HIV-associated lymphoma of the gastrointestinal tract: the University of Toronto AIDS-Lymphoma Study Group experience. Leuk Lymphoma 1995;16:343–349.
Cappell MS, Botros N. Predominantly gastrointestinal symptoms and signs in 11 consecutive AIDS patients with gastrointestinal lymphoma: a multicenter, multiyear study including 763 HIV-seropositive patients. Am J Gastroenterol 1994;89:545–549.
de Carvalho MG, Rodrigues MA, Marques ME, et al. Lesions of the gastrointestinal tract in acquired immunodeficiency syndrome: study of 45 consecutive necropsies. Rev Soc Bras Med Trop 1994;27:135–141.
Rich JD, Crawford JM, Kazanjian SN, et al. Discrete gastrointestinal mass lesions caused by cytomegalovirus in patients with AIDS: report of three cases and review. Clin Infect Dis 1992;15:609–614.
Yeguez JF, Martinez SA, Sands DR, et al. Colorectal malignancies in HIV-positive patients. Am Surg 2003;69:981–987.
Wallace MB, Thomas CR. Gastrointestinal lymphoma and AIDS-related gastrointestinal cancers, in Gastrointestinal Cancers: A Companion to Sleisenger and Fordtran’s Gastrointestinal and Liver Disease. Riustgi AK, ed. W.B. Saunders, Philadelphia, PA, 2003.
Levine AM, Wernz JC, Kaplan L, et al. Low-dose chemotherapy with central nervous system prophylaxis and zidovudine maintenance in AIDS-related lymphoma. A prospective multi-institutional trial. JAMA 1991;266:84–88.
Carucci LR, Halvorsen RA. Abdominal and pelvic CT in the HIV-positive population. Abdom Imaging 2004;29:631–642.
Radin DR, Esplin JA, Levine AM, et al. AIDS-related non-Hodgkin’s lymphoma: abdominal CT findings in 112 patients. Am J Roentgenol 1993;160:1133–1139
Herts BR, Megibow AJ, Birnbaum BA, et al. High-attenuation lymphadenopathy in AIDS patients: significance of findings at CT. Radiology 1992;185:777–781.
Kaplan LD, Abrams DI, Feigal E, et al. AIDS-associated non-Hodgkin’s lymphoma in San Francisco. JAMA 1989;261:719–724
Tirelli U, Errante D, Spina M, et al. Long-term survival of patients with HIV-related systemic non-Hodgkin’s lymphomas. Hematol Oncol 1996;14:7–15.
Levine AM, Sullivan-Halley J, Pike MC, et al. Human immunodeficiency virus-related lymphoma. Prognostic factors predictive of survival. Cancer 1991;68:2466–2472.
Straus DJ, Huang J, Testa MA, Levine AM, et al. Prognostic factors in the treatment of human immunodeficiency virus-associated non-Hodgkin’s lymphoma: analysis of AIDS Clinical Trials Group protocol 142—low-dose versus standard-dose m-BACOD plus granulocyte-macrophage colony-stimulating factor. National Institute of Allergy and Infectious Diseases. J Clin Oncol 1998;16:3601–3606.
Vaccher E, Tirelli U, Spina M, et al. Age and serum lactate dehydrogenase level are independent prognostic factors in human immunodeficiency virus-related non-Hodgkin’s lymphomas: a single-institute study of 96 patients. J Clin Oncol 1996;14:2217–2223.
Vaccher E, Spina M, Talamini R, et al. Improvement of systemic human immunodeficiency virus-related non-Hodgkins lymphoma outcome in the era of highly active antiretroviral therapy. Clin Infect Dis 2003;37:1556–1564.
Besson C, Goubar A, Gabarre J, et al. Changes in AIDS-related lymphoma since the era of highly active antiretroviral therapy. Blood. 2001;98:2339–2344.
Deziel DJ, Hyser MJ, Doolas A, et al. Major abdominal operations in acquired immunodeficiency syndrome. Am Surg 1990;56:445–450.
Wilson SE, Robinson G, Williams RA, et al. Acquired immune deficiency syndrome (AIDS). Indications for abdominal surgery, pathology, and outcome. Ann Surg 1989;210:428–433.
Ratner L, Lee J, Tang S, et al. Chemotherapy for human immunodeficiency virus-associated non-Hodgkin’s lymphoma in combination with highly active antiretroviral therapy. J Clin Oncol 2001;19:2171–2178.
Gill PS, Levine AM, Krailo M et al. AIDS-related malignant lymphoma: results of prospective treatment trials. J Clin Oncol 1987;5:1322–1328.
Kaplan LD, Straus DJ, Testa MA, et al. Low-dose compared with standard-dose m-BACOD chemotherapy for non-Hodgkin’s lymphoma associated with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group. N Engl J Med 1997;336:1641–1648.
Little RF, Pittaluga S, Grant N, et al. Highly effective treatment of acquired immunodeficiency syndrome-related lymphoma with dose-adjusted EPOCH: impact of antiretroviral therapy suspension and tumor biology. Blood 2003;101:4653–4659.
Levine AM, Tulpule A, Espina B, et al. Liposome-encapsulated doxorubicin in combination with standard agents (cyclophosphamide, vincristine, prednisone) in patients with newly diagnosed AIDS-related non-Hodgkin’s lymphoma: results of therapy and correlates of response. J Clin Oncol 2004;22:2662–2670.
Spina M, Jaeger U, Sparano JA, et al. Rituximab plus infusional cyclophosphamide, doxorubicin and etoposide (R-CDE) in HIV-associated non-Hodgkin’s lymphoma: pooled results from three phase II trials. Blood 2005;105:1891–1897.
Friedman SL. Gastrointestinal and hepatobiliary neoplasms in AIDS. Gastroent Clin N Am 1988;17:465–487.
Hanno R, Owen LG, Callen JP. Kaposi’s sarcoma with extensive internal involvement. Int J Dermatol 1979;18:719–721.
Templeton AC. Studies in Kaposi’s sarcoma, post mortem findings and disease patterns in women. Cancer 1972;30:854–867.
Hiesse C, Kriaa F, Riev P, et al. Incidence and type of malignancies occurring after renal transplantation in conventionally and cyclosporine-treated recipients: analysis of a 20-year period in 1600 patients. Transplant Proc 1995;27:972–974.
Shepherd FA, Maher E, Cardella C, et al. Treatment of Kaposi’s sarcoma after solid organ transplantation. J Clin Oncol 1997;15:2371–2377.
Freidman-Kien AE, Laubenstein L, Marmor M, et al. Kaposi’s sarcoma and Pneumocystis pneumonia among homosexual men—New York City and California. MMWR 1981;30:305–308.
Report of the CDC Task Force on Kaposi’s sarcoma and opportunistic infections: Epidemiologic aspects of the current outbreak of Kaposi’s sarcoma and opportunistic infections. N Engl J Med 1982;306:248–252.
Cannon M, Cesarman E. Kaposi’s sarcoma-associated herpes virus and acquired immunodeficiency syndrome-related malignancy. Semin Oncol 2000;27:409–419.
Biggar RJ, Rabkin CS. The epidemiology of AIDS-related neoplasms. Hem Onc Clin N Am 1996;10:997–1010.
Chang Y, Cesarman E, Pessin MS, et al. Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi’s sarcoma. Science 1994;266:1865–1869.
Cannon M, Dollard SC, Black JB, et al. Risk factors for Kaposi’s sarcoma in men seropositive for both HHV8 and HIV. Aids 2003;17:215–222.
Martin JN, Ganem DE, Osmond DH, et al. Sexual transmission and the natural history of human herpes virus 8 infection. N Engl J Med 1998;338:948–954.
Antman K, Chang Y. Kaposi’s sarcoma. N Engl J Med 2000;342:1027–1038.
Kaaya EE, Parravicini C, Ordonez C, et al: Heterogeneity of spindle cells in Kaposi’s sarcoma; comparison of cells in lesions and in culture. J Acquir Immun Defic Synd Hum Retrovirol 1995;10:295–305.
Gill PS, Tsai YC, Rao AP, et al. Evidence for multiclonality in multicentric Kaposi’s sarcoma. Proc Natl Acad Sci USA 1998;95:8257–8261.
Ensoli B, Nakamura S, Salahuddin SZ, et al. AIDS-Kaposi’s sarcoma-derived cells express cytokines with autocrine and paracrine growth effects. Science 1989;243:223–226.
Reichert CM, O’Leary TJ, Levens DL, et al. Autopsy pathology in the acquired immune deficiency syndrome. Am J Path 1983;112:357–382.
Umerah BC, Kaposi’s sarcoma of the oesophagus. Br J Radiol 1980;53:807–808.
Reed WB, Kamath HM, Weiss L. Kaposi’s sarcoma, with emphasis on the internal manifestations. Arch Dermatol 1974;110:115–118.
Krigel RL, Laubenstein LJ, Muggia FM. Kaposi’s sarcoma: a new staging classification. Cancer Treat Report 1983;67:531–534.
Rose HS, Balthazar EJ, Megibow AJ, et al. Alimentary tract involvement in Kaposi’s sarcoma: radiographic and endoscopic findings in 25 homosexual men. Am J Roentgenol 1982;139:661–666.
Ioachim HL, Adsay V, Giancotti FR, et al. Kaposi’s sarcoma of the internal organs, a multiparameter study of 86 cases. Cancer 1995;75:1376–1385.
Freidman SL, Wright TL, Altman DF. Gastrointestinal Kaposi’s sarcoma in patients with acquired immunodeficiency syndrome, endoscopic and autopsy findings. Gastroent 1985;89:102–108.
Saltz RK, Kurtz RC, Lightdale CJ, et al. Kaposi’s sarcoma, gastrointestinal involvement correlation with skin findings and immunologic function. Digest Dis Sci 1984;29:817–823.
Rodgers VD, Kagnoff MF. Gastrointestinal manifestations of the acquired immunodeficiency syndrome. West J Med 1987;146:57–67.
Windle-Taylor PC, Shah N. Oropharyngeal Kaposi’s sarcoma. Report of two cases and review of the literature. J Laryn Otol 1983;97:1665–1671.
Lozada F, Silverman S, Migliorati A, et al. Oral manifestations of tumor and opportunistic infections in the acquired immunodeficiency syndrome (AIDS): findings in 53 homosexual men with Kaposi’s sarcoma. Oral Surg 1983;56:491–493.
Perrone V, Pergola M, Abate G, et al. Protein-losing enteropathy in a patient with generalized Kaposi’s sarcoma. Cancer 1981;47:588–591.
Sharpstone D, Rowbottom A, Nelson M, et al. Faecal alpha-1 antitrypsin as a marker of gastrointestinal disease in HIV antibody positive individuals. Gut 1996;38:206–210.
Wall SD, Freidman SL, Margolis AR. Gastrointestinal Kaposi’s sarcoma in AIDS: radiographic manifestations. J Clin Gastroent 1984;6:165–171.
Port JH, Traube J, Winans CS. The visceral manifestations of Kaposi’s sarcoma. Gastrointest Endoscop 1982;28:179–181.
Lebbe C, Blum L, Pellet C, et al. Clinical and biological impact of antiretroviral therapy with protease inhibitors on HIV-related Kaposi’s sarcoma. AIDS 1998;12:F45-F49.
Sgadari C, Monini P, Barillari G, Ensoli B. Use of HIV protease inhibitors to block Kaposi’s sarcoma and tumour growth. Lancet Oncol 2003;4:537–547.
Gill PS, Loureiro C, Bernstein-Singer M, et al. Clinical Effect of glucocorticoids on Kaposi’s sarcoma related to the acquired immunodeficiency syndrome (AIDS). Ann Int Med 1989;110:937–940.
Nichols CM, Flaitz CM, Hicks MJ. Treating Kaposi’s lesions in the HIV-infected patient. J Am Dert Assoc 1993;124:78–84.
Kaufmann T, Nisce LZ, Coleman M. Case report: Kaposi’s sarcoma of the rectum — treatment with radiation therapy. Br J Radiol 1996;69:573–574.
Dezube BJ. Acquired immunodeficiency syndrome-related Kaposi’s sarcoma: clinical features, staging, and treatment. Semin Oncol 2000;27:424–430.
Northfelt DW, Dezube BJ, Thommes JA, et al. Pegylatedliposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi’s sarcoma: results of a randomized phase III clinical trial. J Clin Oncol 1998;16:2445–2451.
Welles L, Saville MW, Lietzau J, et al. Phase II trial with dose titration of paclitaxel for the therapy of human immunodeficiency virus-associated Kaposi’s sarcoma. J Clin Oncol 1998;16:1112–1121.
Martin DF, Kuppermann BD, Wolitz RA. Oral ganciclovir for patients with cytomegalovirus retinitis treated with a ganciclovir implant. N Engl J Med 1999;340:1063–1070.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Koshy, M., Kauh, J., Gunthel, C. et al. State of the art: Gastrointestinal malignancies in the human immunodeficiency virus (HIV) population. Int J Gastrointest Canc 36, 1–14 (2005). https://doi.org/10.1385/IJGC:36:1:001
Issue Date:
DOI: https://doi.org/10.1385/IJGC:36:1:001